Full Press Release Details
Preliminary Findings
of BrainStorm's Phase IIa Study Reported as "Extremely Optimistic"
TIKVAH, Israel - December 10, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult
stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of
the Company's clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from the ongoing
Phase IIa dose-escalating trial evaluating the company's NurOwn technology, at the 24th International Symposium on
ALS/MND last week in Milan, Italy.
Karussis, the safety data are "impressively positive," with only minimal and transient adverse events, even though the
patients in this study were injected both intrathecally and intramuscularly with up to double the dose of NurOwn cells given in
the Phase I trial. In addition, a number of patients showed some initial indications of clinical improvement. "These
safety observations and initial indications of clinical efficacy are extremely optimistic for the future management of ALS and
the future of cell therapies for neurodegenerative diseases in general," he commented.
As the trial is currently
ongoing, the final data are not yet available for publication. At the conclusion of the trial, the company will release the complete
set of data and analyses.
Cell Therapeutics, Inc.
Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and
commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company
of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
announcement other than historical data and information constitute "forward-looking statements" and involve risks and
uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied
by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could",
"will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to identify these forward-looking
statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited
operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately
protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals;
and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.
These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking
statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and
opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements
to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, performance or achievements.
Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits, President
Phone: +972-3-9236384